Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ramatroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 known ✓ | Q9Y5Y4 | 18/20 | 0.85 |
| ▸ | TBXA2R known ✓ | P21731 | 8/20 | 0.85 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.85 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.85 |
| ▸ | DRD1 | P21728 | 1/20 | 0.85 |
| ▸ | CCKAR | P32238 | 1/20 | 0.85 |
| ▸ | RB1 | P06400 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ramatroban SCHEMBL9869501 | 1.00 | PTGDR2 (0.85) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL29031 | 0.92 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL29030 | 0.92 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL29503087 | 0.92 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL1427851 | 0.92 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL20769768 | 0.92 | PTGDR2 (1.00) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL9870632 | 0.91 | PTGDR2 (0.70) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL1427848 | 0.91 | PTGDR2 (0.98) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| SCHEMBL9429657 | 0.91 | PTGDR2 (0.85) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 | |
| Ramatroban SCHEMBL1427850 | 0.91 | PTGDR2 (0.98) | PTGDR2TBXA2RPTGDRABCB11CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501959-B2 | Cycloalkane[B]indole antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110152338-A1 | CYCLOALKANE[B]INDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| EP-2300425-A2 | CYCLOALKANEÝB¨INDOLE ANGTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010008864-A2 | CYCLOALKANE[B]INDOLE ANGTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152338-A1 | CYCLOALKANE[B]INDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 10/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.